Mr. David Dally (ceo)

Biography

Mr. David Dally was appointed CEO in November 2013. Previously he was CFO; having joined MerLion in March 2007. David qualified as a chartered accountant with Ernst and Young. He joined Amersham plc in 1991 and held a number finance roles including Manager of Strategic Planning and VP Finance North America, managing the merger of Amersham Life Science with Pharmacia Biotech. Since 2002 David has held CFO positions at KuDOS Pharmaceuticals Ltd, an early-stage drug discovery and development in Cambridge, UK, which was sold to Astra Zeneca for $210m, and subsequently at Rhytec Ltd, a medical devices company.  

Research Interest

Toxicology